(Q37830694)

24 August 2017

1 reference

title

Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors (English)

1 reference

24 August 2017

0 references

chronic myeloid leukemia

0 references

1 reference

Bruno Calabretta

1

1 reference

24 August 2017

Paolo Salomoni

series ordinal

2

1 reference

24 August 2017

publication date

21 January 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

52 Suppl 1

1 reference

24 August 2017

page(s)

54-59

1 reference

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Biological consequences of the BCR/ABL fusion gene in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Lysosomes and autophagy in cell death control

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Autophagy: from phenomenology to molecular understanding in less than a decade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Autophagy: dual roles in life and death?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Autophagic cell death: the story of a misnomer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

The role of autophagy in cancer development and response to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Self-eating and self-killing: crosstalk between autophagy and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Growth factor regulation of autophagy and cell survival in the absence of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Autophagy in metazoans: cell survival in the land of plenty

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Autophagy delays apoptotic death in breast cancer cells following DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

The biology of CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Life and death partners: apoptosis, autophagy and the cross-talk between them

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546913

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

21 January 2018

1 reference

12 December 2020

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

1 reference

12 December 2020

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

1 reference

12 December 2020

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

12 December 2020

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

1 reference

12 December 2020

Selective autophagy in cancer development and therapy

1 reference

12 December 2020

A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles

1 reference

12 December 2020

Akt and autophagy cooperate to promote survival of drug-resistant glioma

1 reference

12 December 2020

Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells.

1 reference

12 December 2020

Induction of autophagic cell death in malignant glioma cells by arsenic trioxide.

1 reference

12 December 2020

Autophagy-induced tumor dormancy in ovarian cancer

1 reference

12 December 2020

The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells

1 reference

12 December 2020

Clinical manifestations of chronic granulocytic leukemia.

1 reference

12 December 2020

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

12 December 2020

10.3109/10428194.2010.546913

Identifiers

DOI

1 reference

24 August 2017

1 reference